The Wellcome Trust led a $10 million Series C round for Cell Biosciences, a Palo Alto-based provider of nanoproteomic analysis systems to life science researchers.
The Cell Biosciences platform is a nanofluidic immunoassay system designed to analyze proteins in extremely small biological samples. Researchers use the products to discover subtle details about phosphoprotein signaling in a variety of biological systems.
"We continue to believe that the Cell Biosciences platform is an important enabling technology for biomarker discovery and ultimately can make a real difference in patient care," said Julie Eskay-Eagle, a Cell Biosciences board member and the head of health care investments for the Wellcome Trust.
"This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market," added CEO Tim Harkness.
- read the Cell Biosciences release